Nova Pharma Solutions Bhd (XKLS:03006) Long-Term Capital Lease Obligation : RM0.04 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd Long-Term Capital Lease Obligation?

Nova Pharma Solutions Bhd's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was RM0.04 Mil.

Nova Pharma Solutions Bhd's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (RM0.10 Mil) to Jun. 2023 (RM0.13 Mil) but then declined from Jun. 2023 (RM0.13 Mil) to Dec. 2023 (RM0.04 Mil).

Nova Pharma Solutions Bhd's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (RM0.00 Mil) to Dec. 2022 (RM0.10 Mil) but then declined from Dec. 2022 (RM0.10 Mil) to Dec. 2023 (RM0.04 Mil).

Nova Pharma Solutions Bhd Long-Term Capital Lease Obligation Historical Data

The historical data trend for Nova Pharma Solutions Bhd's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Pharma Solutions Bhd Long-Term Capital Lease Obligation Chart

Nova Pharma Solutions Bhd Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.11

0.05

0.10

0.04

Nova Pharma Solutions Bhd Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial											-	0.04	0.10	0.13	0.04

Nova Pharma Solutions Bhd (XKLS:03006) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Nova Pharma Solutions Bhd Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Pharma Solutions Bhd (XKLS:03006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650

Website

http://www.novapharmasolutions.com

Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd (XKLS:03006) Headlines

No Headlines